Jubilant Pharmova | JUBLPHARMA | NSE - Pharmaceuticals
INR in Million. Fiscal year ends in March. Figures are consolidated and restated..
Upgrade Membership to see 10 year accurate financial statements.
Chart | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Cash and cash equiva... |
| 4,596 | 2,488 | 13,704 | 13,999 | 6,713 |
Short-term investment |
| 0 | 0 | 0 | 0 | 0 |
Accounts receivables |
| 10,053 | 11,308 | 12,715 | 12,932 | 8,199 |
Inventories |
| 12,204 | 13,914 | 14,174 | 18,454 | 11,294 |
Deferred income taxes |
| 44 | 48 | 12 | 3 | 236 |
Other current assets |
| 2,584 | 4,140 | 5,243 | 4,995 | 3,083 |
Total current assets |
| 29,481 | 31,898 | 45,848 | 50,383 | 29,525 |
Gross property plant... |
| 31,040 | 31,925 | 33,962 | 37,507 | 20,079 |
Accumulated Depriciat... |
| 0 | 0 | 0 | 0 | 0 |
Net property, plant and Eq... |
| 31,040 | 31,925 | 33,962 | 37,507 | 20,079 |
Work in Progress |
| 2,107 | 3,001 | 4,916 | 2,636 | 2,778 |
Miscellaneous Investment |
| 1,146 | 1,385 | 1,313 | 947 | 2,560 |
Deferred income taxes |
| 1,676 | 1,810 | 1,809 | 2,403 | 1,630 |
Intangible assets |
| 7,136 | 6,912 | 7,031 | 7,314 | 8,006 |
Goodwill |
| 17,622 | 18,877 | 19,589 | 20,895 | 21,300 |
Other long-term assets |
| 198 | 368 | 217 | 3,132 | 3,304 |
Total non-current assets |
| 60,925 | 64,279 | 68,837 | 74,833 | 59,656 |
Total assets |
| 90,406 | 96,176 | 114,685 | 125,217 | 89,181 |
Short-term debt |
| 2,556 | 2,449 | 4,997 | 6,499 | 200 |
Accounts Payable... |
| 7,495 | 11,362 | 10,201 | 10,903 | 5,205 |
Provisions |
| 358 | 417 | 687 | 988 | 898 |
Taxes Payable |
| 624 | 761 | 276 | 1,059 | 468 |
Deferred Revenues |
| 0 | 0 | 0 | 0 | 0 |
Capital Leases |
| 0 | 0 | 0 | 440 | 501 |
Other current liabilities |
| 5,727 | 5,059 | 4,736 | 6,302 | 3,216 |
Total current liabilities |
| 16,759 | 20,047 | 20,897 | 26,190 | 10,488 |
Long-term debt |
| 35,050 | 30,478 | 42,429 | 37,397 | 25,640 |
Investments Liabilities |
| 0 | 0 | 0 | 0 | 0 |
Deferred tax liabilities |
| 1,864 | 1,631 | 2,024 | 2,634 | 2,473 |
Provisions |
| 807 | 1,071 | 1,143 | 1,508 | 940 |
Capital Leases |
| 0 | 0 | 0 | 1,361 | 1,955 |
Other longterm liabilities |
| 1,958 | 2,600 | 102 | 88 | 270 |
Total non-current liabilities |
| 39,680 | 35,779 | 45,698 | 42,988 | 31,278 |
Total liabilities |
| 56,439 | 55,826 | 66,595 | 69,178 | 41,766 |
Share Capital |
| 156 | 156 | 159 | 159 | 159 |
Share premium |
| 0 | 0 | 0 | 0 | 0 |
Retained earnings |
| 34,205 | 40,710 | 47,930 | 55,880 | 47,256 |
Accumulated other equity |
| 0 | 0 | 0 | 0 | 0 |
Preferred Stock |
| 0 | 0 | 0 | 0 | 0 |
Minority Interest |
| -393 | -515 | 0.99 | 0 | 0.31 |
Total Equity |
| 33,968 | 40,350 | 48,090 | 56,039 | 47,415 |
Total Liabilities and Equity |
| 90,406 | 96,176 | 114,685 | 125,217 | 89,181 |
Cash per Share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
Cash, Current Inv Per share |
| Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |